AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15802445 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 78
Study 12776031 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 100
Study 10488295 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms ITF (n = 20)
Number of subjects: 60
Study 10488295 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 micrograms ITF (n = 20)
Number of subjects: 60
Study 10488295 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms ITF (n = 20)
Number of subjects: 60
Study 10488295 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 8973987 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 gm, 1.2 gm, and 1.8 gm doses of oxaprozin given on an empty stomach in a randomized, crossover trial (n = 35)
Number of subjects: 71
Study 8973987 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 gm once daily for 8 days (n = 12)
Number of subjects: 71
Study 8973987 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 gm once daily for 8 days (n = 24)
Number of subjects: 71
Study 8973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose administration
Number of subjects: 71
Study 8973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose administration
Number of subjects: 71
Study 8973987 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive dosing of oxaprozin
Number of subjects: 71
Study 1383592 — intervention group
Group type: EXPERIMENTAL
Intervention: rheogluman
Number of subjects: 55
Study 1383592 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 55
Study 3902038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 71
Study 3902038 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormethiazole
Number of subjects: 71
Study 3902038 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 71
Study 3902038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 30796580 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-tailored group intervention
Number of subjects: 354
Study 30796580 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 354
Study 30222367 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg/d)
Number of subjects: 100
Study 30222367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27081014 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CCTA)
Number of subjects: 4146
Study 27081014 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 4146
Study 25174283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tratinterol hydrochloride 50 μg/d
Number of subjects: 72
Study 25174283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tratinterol hydrochloride 100 μg/d
Number of subjects: 72
Study 25174283 — intervention group
Group type: EXPERIMENTAL
Intervention: Tratinterol hydrochloride 150 μg/d
Number of subjects: 72
Study 22815653 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based nursing intervention (HQP program)
Number of subjects: 1736
Study 22815653 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1736
Study 20307380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bypass-surgery-first
Number of subjects: 0
Study 20307380 — intervention group
Group type: COMPARATOR
Intervention: Balloon-angioplasty-first
Number of subjects: 0
Study 18834786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral coenzyme Q10, 150 to 180 mg/d, for 7 to 10 days preoperatively
Number of subjects: 30
Study 18834786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant or placebo)
Number of subjects: 30
Study 16103233 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile of patients with the biggest average decrease in hemoglobin (from 14.2 to 12.6 g/dL)
Number of subjects: 0
Study 16103233 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing hemoglobin
Number of subjects: 0
Study 16103233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of anemia at baseline and increases in hemoglobin over 12 months
Number of subjects: 0
Study 11967028 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin alone (0.1 microg/kg/min)
Number of subjects: 46
Study 11967028 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin + low dose insulin (0.1 mU/kg/min)
Number of subjects: 46
Study 11967028 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin + high dose insulin (1.5 mU/kg/min)
Number of subjects: 46
Study 11967028 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1.5 mU/kg/min) + somatostatin
Number of subjects: 46
Study 10589750 — intervention group
Group type: EXPERIMENTAL
Intervention: IT DepoCyt (50 mg doses, up to six doses over 3 months)
Number of subjects: 61
Study 10589750 — intervention group
Group type: COMPARATOR
Intervention: IT methotrexate (10 mg doses, up to sixteen doses over 3 months)
Number of subjects: 61
Study 10589750 — intervention group
Group type: EXPERIMENTAL
Intervention: IT DepoCyt
Number of subjects: 61
Study 10589750 — intervention group
Group type: COMPARATOR
Intervention: IT methotrexate
Number of subjects: 61
Study 10589750 — intervention group
Group type: EXPERIMENTAL
Intervention: DepoCyt
Number of subjects: 61
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston Naming Test (BNT)
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Peabody Picture Vocabulary Test‐Revised (PPVT‐R)
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Word Fluency Test
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened Token Test
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Reporter's Test
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of BNT and PPVT‐R
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of all measures
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: AD subjects trends
Number of subjects: 60
Study 7854529 — intervention group
Group type: COMPARATOR
Intervention: Comparison with NE group
Number of subjects: 60
Study 7854529 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of subjects completing less than four sessions vs. those completing all four
Number of subjects: 60
Study 1378139 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg carvedilol b.i.d.
Number of subjects: 166
Study 1378139 — intervention group
Group type: COMPARATOR
Intervention: 20 mg nifedipine sustained-release (SR)
Number of subjects: 166
Study 6150180 — intervention group
Group type: COMPARATOR
Intervention: Pasteurised human milk and formula
Number of subjects: 226
Study 6150180 — intervention group
Group type: COMPARATOR
Intervention: Raw human milk
Number of subjects: 226
Study 6150180 — intervention group
Group type: COMPARATOR
Intervention: Pasteurised human milk
Number of subjects: 226
Study 6150180 — intervention group
Group type: COMPARATOR
Intervention: Raw human milk and formula
Number of subjects: 226
Study 30387538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy barrier with ceramide
Number of subjects: 0
Study 30387538 — intervention group
Group type: COMPARATOR
Intervention: Ostomy barrier without ceramide
Number of subjects: 0
Study 30387538 — intervention group
Group type: EXPERIMENTAL
Intervention: TEWL measurements
Number of subjects: 0
Study 30387538 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual observation of erythema
Number of subjects: 0
Study 26712530 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 31
Study 26712530 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow expiration with glottis opened in lateral posture (ELTGOL)
Number of subjects: 31
Study 26712530 — intervention group
Group type: COMPARATOR
Intervention: Temporary positive expiratory pressure (TPEP)
Number of subjects: 31
Study 24507168 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm-control strategy
Number of subjects: 2105
Study 24507168 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenient rate-control
Number of subjects: 2105
Study 24507168 — intervention group
Group type: COMPARATOR
Intervention: Strict rate-control
Number of subjects: 2105
Study 24507168 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with preserved systolic function
Number of subjects: 2105
Study 24507168 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure with decreased systolic function
Number of subjects: 2105
Study 22105463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 40
Study 22105463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21152040 — intervention group
Group type: EXPERIMENTAL
Intervention: Amusic patients with right hemisphere damage (RHD)
Number of subjects: 53
Study 21152040 — intervention group
Group type: EXPERIMENTAL
Intervention: Amusic patients with damage to the auditory cortex (AC)
Number of subjects: 53
Study 21152040 — intervention group
Group type: EXPERIMENTAL
Intervention: Amusic patients (both with and without AC damage)
Number of subjects: 53
Study 21152040 — intervention group
Group type: COMPARATOR
Intervention: Non-amusic patients
Number of subjects: 53
Study 17535489 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional intervention (overcoming motivational barriers)
Number of subjects: 198
Study 17535489 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention (implementation intention)
Number of subjects: 198
Study 17535489 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 198
Study 16273135 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptin [HFA] 20 microg
Number of subjects: 28
Study 16273135 — intervention group
Group type: COMPARATOR
Intervention: Meptin [CFC] 20 microg
Number of subjects: 28
Study 12393768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate 30 mg kg(‐1)
Number of subjects: 7
Study 12393768 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 7
Study 9971850 — intervention group
Group type: EXPERIMENTAL
Intervention: Vesta endometrial ablation
Number of subjects: 0
Study 9971850 — intervention group
Group type: COMPARATOR
Intervention: Traditional endometrial resection and rollerball ablation
Number of subjects: 0
Study 7763157 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of 90 mL of saline and dextrose into the knee joint cavity
Number of subjects: 20
Study 7763157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 20
Study 2155569 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐month regimen (self‐administered isoniazid and rifampin daily for 24 weeks, plus pyrazinamide daily during the first 8 weeks)
Number of subjects: 1451
Study 2155569 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐month regimen
Number of subjects: 1451
Study 6455969 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin treatment
Number of subjects: 0
Study 6455969 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential fatty acid treatment
Number of subjects: 0
Study 6455969 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 30325422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse probability weighting
Number of subjects: 0
Study 30325422 — intervention group
Group type: EXPERIMENTAL
Intervention: Selection bias
Number of subjects: 0
Study 30325422 — intervention group
Group type: COMPARATOR
Intervention: Lipoprotein(a)
Number of subjects: 0
Study 28050922 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal paracentesis drainage (APD)
Number of subjects: 161
Study 28050922 — intervention group
Group type: COMPARATOR
Intervention: Non-abdominal paracentesis drainage (non-APD)
Number of subjects: 161
Study 26745361 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercise program for 6 months
Number of subjects: 384
Study 26745361 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention for the first 6 months)
Number of subjects: 384
Study 24304099 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + ADM
Number of subjects: 48
Study 24304099 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 48
Study 22149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth rinse containing zinc acetate (0.3%) and chlorhexidine diacetate (0.025%) with adjunct tongue scraping
Number of subjects: 21
Study 22149929 — intervention group
Group type: COMPARATOR
Intervention: Mouth rinse containing zinc acetate (0.3%) and chlorhexidine diacetate without adjunct tongue scraping
Number of subjects: 21
Study 22149929 — intervention group
Group type: COMPARATOR
Intervention: Inactive rinse sequence with tongue scraping
Number of subjects: 21
Study 22149929 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rinse sequence with or without tongue scraping
Number of subjects: 21
Study 21381407 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bioflora) containing Lactobacillus casei, Lactobacillus plantarum, Streptococcus faecalis, and Bifidobacterium brevis, 5 ml bid for 5 days
Number of subjects: 50
Study 21381407 — intervention group
Group type: COMPARATOR
Intervention: Metronidazol (Flagyl), 500 mg bid for 5 days
Number of subjects: 50
Study 17981316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lara Asthma Symptom Scale (LASS)
Number of subjects: 383
Study 15091283 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-hour nightshift schedule
Number of subjects: 0
Study 15091283 — intervention group
Group type: COMPARATOR
Intervention: 8-hour nightshift schedule
Number of subjects: 0
Study 12467131 — intervention group
Group type: COMPARATOR
Intervention: PUFA diet
Number of subjects: 14
Study 12467131 — intervention group
Group type: COMPARATOR
Intervention: Soy diet
Number of subjects: 14
Study 12467131 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 14
Study 9665010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prograf (0.2 mg/kg per day)
Number of subjects: 80
Study 9665010 — intervention group
Group type: COMPARATOR
Intervention: Neoral (8 mg/kg per day)
Number of subjects: 80
Study 9665010 — intervention group
Group type: EXPERIMENTAL
Intervention: Prograf
Number of subjects: 80
Study 9665010 — intervention group
Group type: COMPARATOR
Intervention: Neoral
Number of subjects: 80
Study 8580802 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary chemotherapy (adriamycin-containing) followed by involved-field radiotherapy; chemotherapy combinations were CHOP (18 patients) and ProMACE/MOPP (8 patients).
Number of subjects: 26
Study 8580802 — intervention group
Group type: COMPARATOR
Intervention: Primary chemotherapy (adriamycin-containing) without radiotherapy.
Number of subjects: 26
Study 2635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diazepam 0.3 mg/kg
Number of subjects: 9
Study 2635496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiopental 6.0 mg/kg
Number of subjects: 9
Study 1274890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education program
Number of subjects: 0
Study 1274890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31324490 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV
Number of subjects: 7422
Study 31324490 — intervention group
Group type: COMPARATOR
Intervention: No HIV (Control group)
Number of subjects: 7422
Study 31324490 — intervention group
Group type: EXPERIMENTAL
Intervention: Having at least 1 comorbidity
Number of subjects: 7422
Study 29154054 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract capsules (200mg) twice a day for 28 days
Number of subjects: 60
Study 29154054 — intervention group
Group type: COMPARATOR
Intervention: Wheat flour capsules (200mg) twice a day for 28 days (Control)
Number of subjects: 60
Study 25950160 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC
Number of subjects: 60
Study 25950160 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 60
Study 25950160 — intervention group
Group type: EXPERIMENTAL
Intervention: SeT
Number of subjects: 60
Study 25950160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavity
Number of subjects: 60
Study 25950160 — intervention group
Group type: COMPARATOR
Intervention: Sound teeth
Number of subjects: 60
Study 23203401 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic peritoneal vaginoplasty
Number of subjects: 40
Study 23203401 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sigmoid vaginoplasty
Number of subjects: 40
Study 21620309 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received an additional 30-minute session on safe and effective use of heat, cold, and relaxation breathing, along with hot and cold packs and relaxation breathing instruction for 2 weeks.
Number of subjects: 53
Study 21620309 — intervention group
Group type: COMPARATOR
Intervention: Control group attended a 30-minute educational session on safe use of over-the-counter medications.
Number of subjects: 53
Study 20170044 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug
Number of subjects: 0
Study 16957999 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hydration (NH)
Number of subjects: 0
Study 15243277 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 90
Study 15243277 — intervention group
Group type: EXPERIMENTAL
Intervention: EPT (1 mg 17beta‐estradiol combined with 0.5 mg norethisterone acetate)
Number of subjects: 90
Study 15243277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 11403659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracardiac microaxial pump (Group 1)
Number of subjects: 42
Study 11403659 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass setup (Group 2)
Number of subjects: 42
Study 9039174 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole, 200 mg twice daily for the first week of each month for 2 consecutive months
Number of subjects: 73
Study 9039174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 9039174 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 73
Study 8297546 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg single dose)
Number of subjects: 0
Study 8297546 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin with cholestyramine (CME)
Number of subjects: 0
Study 8297546 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin with niacin and propranolol
Number of subjects: 0
Study 8297546 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin in patients receiving digoxin
Number of subjects: 0
Study 3306545 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Healon
Number of subjects: 38
Study 3306545 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 38
Study 30376866 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 195
Study 27410770 — intervention group
Group type: EXPERIMENTAL
Intervention: CO inhalation (1.2 ml kg(‐1) CO for 30 seconds once per day for 10 days)
Number of subjects: 18
Study 27410770 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation (room air)
Number of subjects: 18
Study 24211857 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch isolation technique
Number of subjects: 850
Study 24211857 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 850
Study 22516905 — intervention group
Group type: EXPERIMENTAL
Intervention: short‐set long‐interval condition (SSLI; 12 sets of 3 repetitions with a 60‐second interval between sets)
Number of subjects: 19
Study 22516905 — intervention group
Group type: COMPARATOR
Intervention: short‐set short‐interval condition (SSSI; 12 sets of 3 repetitions with a 27.3‐second interval between sets)
Number of subjects: 19
Study 22516905 — intervention group
Group type: COMPARATOR
Intervention: long‐set long‐interval (LSLI; 6 sets of 6 repetitions with a 60‐second rest interval between sets)
Number of subjects: 19
Study 20098455 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 0
Study 20098455 — intervention group
Group type: COMPARATOR
Intervention: G-CSF mobilization
Number of subjects: 0
Study 18003764 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete remission
Number of subjects: 86
Study 18003764 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial remission
Number of subjects: 86
Study 18003764 — intervention group
Group type: COMPARATOR
Intervention: No remission
Number of subjects: 86
Study 16441791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerasorb (beta-tricalcium phosphate)
Number of subjects: 17
Study 16441791 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone graft
Number of subjects: 17
Study 15182393 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (2.0 g/d)
Number of subjects: 7
Study 15182393 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA (2.0 g/d)
Number of subjects: 7
Study 15182393 — intervention group
Group type: EXPERIMENTAL
Intervention: STA (1.0 g/d) + GLA (0.9 g/d)
Number of subjects: 7
Study 15182393 — intervention group
Group type: EXPERIMENTAL
Intervention: STA (<1.0 g/d)
Number of subjects: 7
Study 15182393 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA or GLA (2.0 g/d)
Number of subjects: 7
Study 15182393 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 7
Study 11777488 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (ORTHO EVRA/EVRA) applied 1/week for three cycles (3 weeks/cycle)
Number of subjects: 24
Study 11777488 — intervention group
Group type: EXPERIMENTAL
Intervention: Contraceptive patch (ORTHO EVRA/EVRA)
Number of subjects: 24
Study 9107203 — intervention group
Group type: EXPERIMENTAL
Intervention: Process consultation with nurse manager-consultant meetings
Number of subjects: 13
Study 9107203 — intervention group
Group type: EXPERIMENTAL
Intervention: Process consultation with nurse manager-consultant meetings (high-dose)
Number of subjects: 13
Study 9107203 — intervention group
Group type: EXPERIMENTAL
Intervention: Process consultation with nurse manager-consultant meetings (low-dose)
Number of subjects: 13